Bisphosphonates in the treatment of thalassemia-associated osteoporosis. - Wikidata - wikimedia - TriplyDB

Bisphosphonates in the treatment of thalassemia-associated osteoporosis.

Bisphosphonates in the treatment of thalassemia-associated osteoporosis.

http://www.wikidata.org/entity/Q37117363

about

Beta-thalassemia Treatment for osteoporosis in people with ß-thalassaemia Treatment for osteoporosis in people with ß-thalassaemia Rare causes of osteoporosis Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial.Predictors of bone disease in Egyptian prepubertal children with β-thalassaemia major Vitamin D Receptor (VDR) Gene Polymorphisms (FokI, BsmI) and their Relation to Vitamin D Status in Pediatrics βeta Thalassemia Major.Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review.Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study.Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits.Bone disease in adult patients with β-thalassaemia major: a case-control study.

P2860

Q21202886-389E419B-9632-4F49-9679-DEADCB0A3849 Q24186036-62E56664-335B-4C10-9F6E-16EB98C89F76 Q24200472-B3BEF5C2-DDA1-4575-A9E1-65688138DB70 Q26775750-1AB3C920-910D-4BB5-A1EC-D0E08195C807 Q34941788-FF68DFC0-C13A-4966-8B26-A75C6FCEEB24 Q35770778-61FC045B-197A-4436-977F-77B519C79BC5 Q36679586-6C701629-66F8-4F71-8A0F-EBAA70C11D64 Q37401130-B1B01A40-488A-4F75-951B-52479BD429EC Q38471926-9DB2724B-8F35-464B-8CB0-25A3F0D1C835 Q43265083-C5455DFD-AA02-4340-984B-4BEB96C306A5 Q44552513-9BB79EAD-A491-4751-B2DD-687175D7C0FD

P2860

Bisphosphonates in the treatment of thalassemia-associated osteoporosis.

http://www.wikidata.org/entity/Q37117363

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Bisphosphonates in the treatment of thalassemia-associated osteoporosis.

@en

Bisphosphonates in the treatment of thalassemia-associated osteoporosis.

@nl

type

label

Bisphosphonates in the treatment of thalassemia-associated osteoporosis.

@en

Bisphosphonates in the treatment of thalassemia-associated osteoporosis.

@nl

prefLabel

Bisphosphonates in the treatment of thalassemia-associated osteoporosis.

@en

Bisphosphonates in the treatment of thalassemia-associated osteoporosis.

@nl

P1433

Q37117363-4DC9708F-DB61-46A3-B60F-AF9463ED1421

P1476

Q37117363-1374D56C-8D84-451C-9AAC-327303B83FE5

P2093

Q37117363-1CFA3A26-6024-4354-BFFB-622099A8E574

Q37117363-368D1EB1-4316-4C68-9ABE-9BD03B58973C

Q37117363-4B64D599-2E43-470D-BC63-E3C1F5B00219

Q37117363-53E76081-B4A9-4431-BFBD-ADD1277D6A4D

Q37117363-570E7567-4529-4CDA-94A5-0803A090C840

Q37117363-6F9B015F-6434-4DE4-BF75-1796CA557094

Q37117363-DA52B16D-D726-425E-9A23-E94983349008

Q37117363-E5BC52F9-E5C5-4A02-AED9-2C368A33B1A9

Q37117363-EA23AE08-079D-4134-B034-C32CA48EBD33

P2860

Q37117363-16C63B38-A9FD-4724-A1C5-3E0E0FCC8DCB

Q37117363-3BB4DAEF-1B41-408D-B792-8848B1DC08E9

Q37117363-48466C31-BE18-4205-9E8E-AD48E1BD106C

Q37117363-744793E9-9B7A-417D-BB2C-CE0B916554C6

Q37117363-834743AC-BE4C-4005-AEDE-C2DDFCA7EBFC

Q37117363-91165D08-24C7-496F-A437-8D4315A8473A

Q37117363-96F876A6-A0BA-4556-9BB5-CC63B1245B16

Q37117363-A6834785-384D-442F-ACAC-3B9C2EF4688D

Q37117363-A7967350-C9AE-4A33-9B86-2613594E2F03

Q37117363-A891A0CD-F83D-4639-A97C-59FD4957C12A

P2888

Q37117363-A5F7E5C6-54EB-4C3C-9024-67D51E64D4C8

P304

Q37117363-146BA1FD-675D-41D9-8EC4-032C3478081D

P31

Q37117363-838DBEF0-B17C-4373-90EB-EA70F1003A48

P356

Q37117363-04230A81-A296-419E-85EA-C0B124E6A5F4

P433

Q37117363-9E898320-FA10-4E0E-AB96-68B3880EBFBC

P478

Q37117363-C12356A4-6DB9-4B85-BDBF-38B38EA5068C

P577

Q37117363-832CFE32-2D10-451E-A770-9C4EAF6E53C0

P698

Q37117363-3667EFB9-CFE4-4B1E-B116-92F16D4BEBD0

P921

Q37117363-012BA4B2-EF59-460A-A1C1-07BF9ED86548

P356

P1433

Journal of Endocrinological Investigation

P1476

Bisphosphonates in the treatment of thalassemia-associated osteoporosis.

@en

P2093

Frisina N

http://www.w3.org/2001/XMLSchema#string

Gaudio A

http://www.w3.org/2001/XMLSchema#string

Lasco A

http://www.w3.org/2001/XMLSchema#string

Macrì I

http://www.w3.org/2001/XMLSchema#string

Meo A

http://www.w3.org/2001/XMLSchema#string

Morabito N

http://www.w3.org/2001/XMLSchema#string

Morgante S

http://www.w3.org/2001/XMLSchema#string

Trifiletti A

http://www.w3.org/2001/XMLSchema#string

Xourafa A

http://www.w3.org/2001/XMLSchema#string

P2860

New approaches for interpreting projected bone densitometry data.

Bone resorption is increased in young adults with thalassaemia major.

Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data.

Bone densitometry of the spine and femur in children by dual-energy x-ray absorptiometry.

New bisphosphonates in the treatment of bone diseases.

Prevalence of fractures among the Thalassemia syndromes in North America.

The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches.

Bisphosphonate-induced osteonecrosis of the jaw.

Regulation of osteoclast function.

Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major.

P2888

P304

181-184

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/BF03345587

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18362512

http://www.w3.org/2001/XMLSchema#string

P921